NCT03667092View on ClinicalTrials.gov

Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor

NACompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

May 22, 2024

Study Completion Date

May 22, 2024

Conditions
Midgut Neuroendocrine Tumors
Interventions
BIOLOGICAL

non-drug intervention type

8 peripheral blood samples (8x5ml) will be obtained at different times ; before, during and after treatment

Trial Locations (1)

31059

CHU de Toulouse, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT03667092 - Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor | Biotech Hunter | Biotech Hunter